Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Assertio Holdings, Inc.

Get SEC filing alerts via email and in your feed for Assertio Holdings, Inc.

ASRT

Assertio Holdings, Inc.

About Assertio Holdings, Inc.

Assertio Holdings, Inc. is a U.S.-based pharmaceutical company specializing in oncology, neurology, and pain management. It markets differentiated, approved products such as ROLVEDON, Sympazan, INDOCIN, Otrexup, SPRIX, and CAMBIA primarily through a sales force and omni-channel promotional model targeting hospitals, clinics, and pharmacies. Assertio relies on third-party manufacturing and focuses on patient-centric services, patent protection, and strategic product acquisitions to sustain competitive advantage and commercial growth.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Assertio Holdings, Inc.

1
1
Assertio Holdings, Inc. Assertio Holdings Reports 62.5% Revenue Decline and $18.9 Million Net Loss in Q1 2026

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Assertio Holdings, Inc. Assertio Holdings Reports $30.4 Million Net Loss and Revenue Decline for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Assertio Holdings, Inc. Assertio Holdings Reports $49.5M Revenue Growth Driven by ROLVEDON Sales

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Assertio Holdings, Inc. Assertio Holdings Reports Q2 2025 Revenue Decline and Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Assertio Holdings, Inc. Assertio Holdings Reports $13.5 Million Net Loss in Q1 2025 Amid Revenue Decline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Assertio Holdings, Inc. Assertio Holdings Reports $21.6 Million Net Loss for Fiscal Year 2024, Improved from $331.9 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Assertio Holdings, Inc. Assertio Holdings Reports Decline in Revenues, Improvement in Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments